Co-Diagnostics Statistics
Total Valuation
Co-Diagnostics has a market cap or net worth of $7.31 million. The enterprise value is -$2.66 million.
Important Dates
The next estimated earnings date is Thursday, March 19, 2026, after market close.
| Earnings Date | Mar 19, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
Co-Diagnostics has 2.26 million shares outstanding. The number of shares has increased by 11.72% in one year.
| Current Share Class | 2.26M |
| Shares Outstanding | 2.26M |
| Shares Change (YoY) | +11.72% |
| Shares Change (QoQ) | +14.45% |
| Owned by Insiders (%) | 4.57% |
| Owned by Institutions (%) | 11.02% |
| Float | 2.15M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 14.39 |
| Forward PS | 11.41 |
| PB Ratio | 0.13 |
| P/TBV Ratio | 0.53 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Financial Ratio HistoryEnterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.81, with a Debt / Equity ratio of 0.04.
| Current Ratio | 3.81 |
| Quick Ratio | 3.36 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -62.12% and return on invested capital (ROIC) is -119.76%.
| Return on Equity (ROE) | -62.12% |
| Return on Assets (ROA) | -37.92% |
| Return on Invested Capital (ROIC) | -119.76% |
| Return on Capital Employed (ROCE) | -86.56% |
| Weighted Average Cost of Capital (WACC) | 9.95% |
| Revenue Per Employee | $3,848 |
| Profits Per Employee | -$243,799 |
| Employee Count | 132 |
| Asset Turnover | 0.01 |
| Inventory Turnover | 0.28 |
Taxes
| Income Tax | -1.15M |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -79.81% in the last 52 weeks. The beta is 1.40, so Co-Diagnostics's price volatility has been higher than the market average.
| Beta (5Y) | 1.40 |
| 52-Week Price Change | -79.81% |
| 50-Day Moving Average | 3.24 |
| 200-Day Moving Average | 8.22 |
| Relative Strength Index (RSI) | 54.77 |
| Average Volume (20 Days) | 161,577 |
Short Selling Information
The latest short interest is 2.25 million, so 99.81% of the outstanding shares have been sold short.
| Short Interest | 2.25M |
| Short Previous Month | 646,208 |
| Short % of Shares Out | 99.81% |
| Short % of Float | n/a |
| Short Ratio (days to cover) | 1.19 |
Income Statement
In the last 12 months, Co-Diagnostics had revenue of $507,892 and -$32.18 million in losses. Loss per share was -$29.01.
| Revenue | 507,892 |
| Gross Profit | 172,843 |
| Operating Income | -35.53M |
| Pretax Income | -33.33M |
| Net Income | -32.18M |
| EBITDA | -34.33M |
| EBIT | -35.53M |
| Loss Per Share | -$29.01 |
Full Income StatementBalance Sheet
The company has $11.44 million in cash and $1.47 million in debt, with a net cash position of $9.97 million or $4.42 per share.
| Cash & Cash Equivalents | 11.44M |
| Total Debt | 1.47M |
| Net Cash | 9.97M |
| Net Cash Per Share | $4.42 |
| Equity (Book Value) | 39.83M |
| Book Value Per Share | 24.82 |
| Working Capital | 10.36M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -$31.17 million and capital expenditures -$641,065, giving a free cash flow of -$31.81 million.
| Operating Cash Flow | -31.17M |
| Capital Expenditures | -641,065 |
| Free Cash Flow | -31.81M |
| FCF Per Share | -$14.10 |
Full Cash Flow StatementMargins
| Gross Margin | 34.03% |
| Operating Margin | -6,995.70% |
| Pretax Margin | -6,562.78% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
Co-Diagnostics does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -11.72% |
| Shareholder Yield | -11.72% |
| Earnings Yield | -440.22% |
| FCF Yield | -435.14% |
Analyst Forecast
The average price target for Co-Diagnostics is $90.00, which is 2,677.78% higher than the current price. The consensus rating is "Buy".
| Price Target | $90.00 |
| Price Target Difference | 2,677.78% |
| Analyst Consensus | Buy |
| Analyst Count | 3 |
| Revenue Growth Forecast (5Y) | 122.93% |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsFair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
Stock Splits
The last stock split was on January 2, 2026. It was a reverse split with a ratio of 1:30.
| Last Split Date | Jan 2, 2026 |
| Split Type | Reverse |
| Split Ratio | 1:30 |
Scores
Co-Diagnostics has an Altman Z-Score of -1.69 and a Piotroski F-Score of 1. A Z-score under 3 suggests an increased risk of bankruptcy.
| Altman Z-Score | -1.69 |
| Piotroski F-Score | 1 |
